DNA — Ginkgo Bioworks Holdings, Inc. stock price, charts and financials

Latest market price

7.88

+0.04+0.51%

Overview Short InterestFilings

DNAQT34Ginkgo Bioworks Holdings, Inc.·NYSE

Overview Short InterestFilings

7.88+0.51%

News

Up 0.5% — Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains? (zacks.com).

Medium confidence

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

NKTR-1.84%$67.10 RAPP-3.58%$40.45 GHRS-1.60%$28.26 ZYME-3.31%$26.57 AGIO-1.61%$33.07 ZBIO-1.47%$31.50 GPCR-0.28%$35.00 NUVB-3.62%$5.85

Snapshot

Index	-	P/E	-	EPS (ttm)	-5.02	Insider Own	-	Shs Outstand	65.32M	Perf Week	16.74%

Market Cap	514.76M	Forward P/E	-	EPS next Y	-3.44	Insider Trans	-0.34%	Shs Float	47.85M	Perf Month	2.20%

Enterprise Value	616.76M	PEG	-	EPS next Q	-0.58	Inst Own	-	Short Float	14.35%	Perf Quarter	-14.07%

Income	-292.00M	P/S	4.64	EPS this Y	13.75%	Inst Trans	-	Short Ratio	5.76	Perf Half Y	14.04%

Sales	111.00M	P/B	1.23	EPS next Y	20.55%	ROA	-29.37%	Short Interest	6.87M	Perf YTD	-5.17%

Book/sh	6.43	P/C	1.70	EPS next 5Y	-	ROE	-60.21%	52W High	17.58 -55.18%	Perf Year	-28.82%

Cash/sh	4.62	P/FCF	-	EPS past 3/5Y	-	ROIC	-31.63%	52W Low	5.37 46.74%	Perf 3Y	-90.25%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-29.15% 17.16%	Gross Margin	80.09%	Volatility	7.31% 6.14%	Perf 5Y	-97.99%

Dividend TTM	-	EV/Sales	5.56	EPS Y/Y TTM	52.37%	Oper. Margin	-259.86%	ATR (14)	0.49	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	4.57	Sales Y/Y TTM	-51.10%	Profit Margin	-259.96%	RSI (14)	59.48	Recom	3.00

Dividend Gr. 3/5Y	-	Current Ratio	4.57	EPS Q/Q	31.82%	SMA20	11.08%	Beta	1.83	Target Price	5.00

Payout	0.00%	Debt/Eq	0.82	Sales Q/Q	-60.00%	SMA50	3.56%	Rel Volume	1.54	Prev Close	7.84

Employees	485	LT Debt/Eq	0.82	Earnings	Nov 05	SMA200	-4.50%	Avg Volume	1.14M	Price	7.88

IPO Date	Apr 19, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	16.20% -16.19%	Net Debt/EBITDA	-1.53	Volume	1,754,876	Change	0.51%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-09-26	Reiterated	Oppenheimer		$5.00
Aug-07-26	Downgrade	TD Cowen	Buy → Hold
Aug-25-25	Reiterated	BTIG	Sell	$7.00 → $9.00
Aug-23-24	Reiterated	BTIG	Sell	$6.00 → $7.00
May-15-24	Downgrade	BTIG	Neutral → Sell
May-10-24	Downgrade	William Blair	Market Perform → Underperform
Nov-15-23	Downgrade	Raymond James	Outperform → Market Perform
Nov-14-23	Downgrade	Raymond James	Outperform → Market Perform
Nov-09-23	Downgrade	BTIG	Buy → Neutral
Jun-02-23	Downgrade	Goldman Sachs	Neutral → Sell

Latest News· Times ET

Sep-18-26

Sep-18-2609:35AM

Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?zacks.com

Sep-16-26

Sep-16-2603:15PM

Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Factszacks.com

05:52AM

Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Databusinesswire.com

Sep-10-26

Sep-10-2608:00AM

Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA MedicinesYahoo

Sep-04-26

Sep-04-2603:01AM

BTIG Reiterates Sell on Ginkgo Bioworks Holdings, Maintains $5 Price TargetBenzinga

Sep-01-26

Sep-01-2611:04AM

Ginkgo Bioworks: Another Pivot, Still No Proof Of Product-Market FitSeekingAlpha

Aug-19-26

Aug-19-2612:15PM

DNA X, Inc. Reports Second Quarter 2026 Financial Resultsglobenewswire.com

06:08AM

Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On WednesdayBenzinga

Aug-18-26

Aug-18-2606:45AM

Andrea Guerra, Prada CEO, Says Craftsmanship Is ‘The DNA Of Everything'youtube.com

Aug-08-26

Aug-08-2611:18AM

TD Cowen Downgrades Ginkgo Bioworks Holdings (DNA)Fintel

Aug-07-26

Aug-07-2608:04PM

Ginkgo Bioworks Q2 Earnings Call Highlightsmarketbeat.com

Aug-06-26

Aug-06-2603:40AM

Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcriptseekingalpha.com

Aug-05-26

Aug-05-2604:30AM

UW Credit Union Selects DNA from Fiserv to Power its Next Stage of Growthglobenewswire.com

03:25AM

Kane Biotech Announces Engagement of DNA Advisorsglobenewswire.com

Aug-04-26

Aug-04-2608:46PM

Core DNA: Coreweave and Nebius Couldn't Be More Different and Why It Matters247wallst.com

Company

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	111	170	227	—	—	—	—	—
Cost of Goods Sold Incl. D&A	23	32	39	—	—	—	—	—
Gross Profit	90	139	188	—	—	—	—	—
Selling, General and Administrative Excl. Other	160	183	246	—	—	—	—	—
Research and Development	215	244	424	—	—	—	—	—
Other Operating Expense	5	27	78	—	—	—	—	—
Operating Income	-291	-315	-560	—	—	—	—	—
Interest Expense	0	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-6	2	12	—	—	—	—	—
Net Income Before Taxes	-295	-314	-548	—	—	—	—	—
Income Taxes	-1	-1	0	—	—	—	—	—
Consolidated Net Income	-292	-313	-547	—	—	—	—	—
Net Income From Continuing Operations	-295	-313	-547	—	—	—	—	—
Net Income	-292	-313	-547	—	—	—	—	—
EPS (Recurring)	-5.02	-5.64	-10.54	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-5.02	-5.64	-10.54	—	—	—	—	—
EPS (Diluted)	-5.02	-5.64	-10.54	—	—	—	—	—
EBITDA	-209	-255	-484	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	4.40	2.69	2.25	—	—	—	—	—
Gross Margin	81.08	81.76	82.82	—	—	—	—	—
Operating Margin	-262.16	-185.29	-246.70	—	—	—	—	—
Net Margin	-263.06	-184.12	-240.97	—	—	—	—	—
Shares Outstanding	62	55	52	—	—	—	—	—
Market Capitalization	489	457	511	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HENRY CHRISTIAN O	Director	Sep 15 '26	Sale	7.08	5,000	35,405	19,310	Sep 16
Coen Steven P.	See remarks	Aug 24 '26	Sale	6.98	330	2,302	51,851	Aug 25
Coen Steven P.	See remarks	Aug 21 '26	Option Exercise	0.00	743	0	52,181	Aug 25
Coen Steven P.	See remarks	Jul 17 '26	Sale	7.90	752	5,943	51,438	Jul 20
Coen Steven P.	See remarks	Jul 16 '26	Option Exercise	0.00	1,486	0	52,190	Jul 20
Coen Steven P.	See remarks	May 22 '26	Sale	8.33	307	2,559	50,704	May 26
Coen Steven P.	See remarks	May 21 '26	Option Exercise	0.00	743	0	51,011	May 26
Coen Steven P.	See remarks	Apr 17 '26	Sale	7.95	324	2,576	50,268	Apr 20
Coen Steven P.	See remarks	Apr 16 '26	Option Exercise	0.00	743	0	50,592	Apr 20
Coen Steven P.	See remarks	Apr 13 '26	Sale	6.41	33,171	212,759	49,849	Apr 14
Coen Steven P.	See remarks	Apr 10 '26	Option Exercise	0.00	73,921	0	83,020	Apr 14
Shetty Reshma P.	See remarks	Apr 10 '26	Sale	6.43	124,727	802,494	436,422	Apr 13
Canton Barry	10% Owner	Apr 10 '26	Sale	6.43	124,727	802,494	436,422	Apr 13
Shetty Reshma P.	See remarks	Apr 09 '26	Option Exercise	0.00	251,786	0	561,149	Apr 13
Canton Barry	10% Owner	Apr 09 '26	Option Exercise	0.00	251,786	0	561,149	Apr 13

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.